Legend Biotech (LEGN) Accumulated Expenses (2019 - 2026)

Legend Biotech (LEGN) has 7 years of Accumulated Expenses data on file, last reported at $195.4 million in Q4 2025.

• Quarterly Accumulated Expenses rose 17.57% year-over-year to $195.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $195.4 million (up 17.57% YoY) and the FY2025 annual result came in at $195.4 million, up 17.57% from the prior year.
• Accumulated Expenses improved to $195.4 million in Q4 2025, from $147.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $195.4 million in Q4 2025 to a low of $80096.0 in Q1 2021.
• A 5-year average of $128.1 million and a median of $141.7 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2021 — Accumulated Expenses jumped 128705.84% — and 2023, when it tumbled 33.57%.
• Tracing LEGN's Accumulated Expenses over 5 years: stood at $123.6 million in 2021, then surged by 49.01% to $184.1 million in 2022, then plunged by 33.57% to $122.3 million in 2023, then soared by 35.89% to $166.2 million in 2024, then climbed by 17.57% to $195.4 million in 2025.
• The last three Accumulated Expenses figures came in at $195.4 million (Q4 2025), $147.2 million (Q3 2025), and $138.8 million (Q2 2025), per Business Quant data.